Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 22, Issue 5, 2012, Pages 836-841

  Zhao, Lijun ^a   Zhao, Xin ^a,b   Shen, Danhua ^a   Li, Xiaoping ^a   Wang, Jianliu ^a   Wang, Huilan ^b   Wei, Lihui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

CD1a; Dendritic cell; Endometrial endometrioid adenocarcinoma; HLA DR; S100

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; HLA DR ANTIGEN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN S 100; T6 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DENDRITIC CELL; ENDOMETRIUM CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; DENDRITIC CELLS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE;

EID: 84863677895     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31825401c6     Document Type: Article

References (19)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505. (Pubitemid 41111699)
2. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: a study of a total population. Cancer. 1991;67:3093-3103.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. (Pubitemid 30082188)
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. (Pubitemid 32878711)
5. Bissell MJ, Radisky D. Putting tumours in context. Nature Rev Cancer. 2001;1:46-54. (Pubitemid 33741880)
6. Bissell MJ, Radisky DC, Rizki A, et al. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation. 2002;70:537-546. (Pubitemid 36194318)
7. Chen C, Zhu YB, Qu QX, et al. CD40-activated apoptotic tumor cellYpulsed dendritic cell could potentially elicit antitumor immune response: involvement of up-regulation of B7-H3 expression. J Immunother. 2009;32: 29-35.
8. Honig A, Schaller N, Dietl J, et al. S100 as an immunohistochemically detected marker with prognostic significance in endometrial carcinoma. Anticancer Res. 2005;25:1547-1553.
9. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DCLamp+ dendritic cells in tumor sites is associated with efficient T-cellYmediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 2004;64:2192-2198. (Pubitemid 38339472)
10. Mitsuhiko I, Hisashi SH, Akiko M, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Cancer. 2003;104: 92-97.
11. Donato R. S100: a multigenic family of calcium modulated proteins of the EF hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637-638.
12. Chang XY, Tang JM, Zhu XJ, et al. Immunohistochemical quantity analysis of dendritic cells and T lymphocytes in human cervical intraepithelial neoplasia and invasive carcinoma. Acta Anatomica Sinica. 2007;38:75-80.
13. Xu LX, Feng J, Tang JM, et al. The expression of major histocompatibility complex in human ovarian epithelial carcinoma. Journal of Beijing Medical University. 2000;32:496-499.
14. Elza C, Cornelis JH, Han JM, et al. Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. Clin Cancer Res. 2008;14:1073-1079.
15. Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther. 2008;8:561-572. (Pubitemid 351818351)
16. Lazars AC, Chatzigianni EB, Xidias G, et al. Tissue evaluation of immune markers in endometrial and cervical carcinomas. J Exp Clin Cancer Res. 2004;23:269-275. (Pubitemid 38943559)
17. Coventry BJ, Lee PL, Gibbs D, et al. Dendritic cell density and activation status in human breast cancerVCD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer. 2002;86:546-551. (Pubitemid 34185090)
18. Nagorsen D, Voigt S, Berg E, et al. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007;5:62.
19. Dallal RM, Christakos P, Lee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery. 2002;131:135-138. (Pubitemid 34169537)